Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Emerging Paradigms in Severe Asthma Management: Integrating Technology and Personalized...
share announcement

Emerging Paradigms in Severe Asthma Management: Integrating Technology and Personalized Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: 30 October 2024 | Viewed by 714

Special Issue Editors

Dr. Rudolfo Álvarez-Sala-Walther

E-Mail Website
Guest Editor
Respiratory Medicine Service, Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, Madrid, Spain
Interests: clinical research; chronic obstructive pulmonary disease; clinical studies; lung diseases; spirometry; asthma management; airway obstruction; allergic diseases; asthma; lung
Dr. Santiago Quirce

E-Mail Website
Guest Editor
Department of Allergy, Hospital Universitario La Paz, Institute for Health Research (IdiPAZ), CIBER of Respiratory Diseases (CIBERES), Madrid, Spain
Interests: allergic asthma; occupational asthma; eosinophilic asthma; grass allergy

Special Issue Information

Dear Colleagues,

Severe uncontrolled asthma is defined as asthma that remains insufficiently controlled despite receiving intensive asthma treatment after asthma diagnosis has been confirmed and considering comorbidities that may mimic asthma. The prevalence of severe uncontrolled asthma is estimated at 5% of all asthma cases. However, these patients account for more than half of total asthma expenditure, including direct and indirect costs. In this context, biological drugs have emerged as a promising option to address severe asthma. These medications target the specific immune system mechanisms involved in bronchial inflammation, providing a more precise and effective approach. By targeting specific cytokines and immune cells, biologics can help reduce symptoms, improve lung function, and decrease the frequency of exacerbations in patients with severe asthma. Although this therapeutic approach represents a significant advance, ongoing research and personalization of treatments are essential to optimize outcomes for people with this difficult respiratory condition.

A key theme of this Special Issue is the role of technology, particularly artificial intelligence (AI), telemedicine, big data, and bioinformatics, in transforming asthma care. The integration of these technologies is reshaping the management of asthma, enhancing diagnostic precision, personalizing treatment plans, and improving patient outcomes.

Overall, we aim for this Special Issue to serve as a comprehensive resource for clinicians, researchers, and policymakers, providing a multi-dimensional perspective on the latest trends in severe asthma management, with a particular focus on the role of technology and personalized treatment approaches.

Dr. Rudolfo Álvarez-Sala-Walther
Dr. Santiago Quirce
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • precision medicine
  • new technologies
  • artificial intelligence
  • cardiovascular comorbidities
  • biological treatment
  • efficacy evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 255 KiB  
Article
Cardiovascular Events in Patients with Severe Asthma—A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2
by Paula Granda, Elena Villamañán, Daniel Laorden, Carlos Carpio, Victoria Collada, Javier Domínguez-Ortega, Leticia de las Vecillas, David Romero-Ribate, Omar Fabián Chaparro-Díaz, Teresa Lázaro Miguel-Sin, Daniela Jose Alloca-Álvarez, Jorge Mauricio Correa-Borit, Itsaso Losantos, Patricia Mir-Ihara, Emilio José Narváez-Fernández, Santiago Quirce and Rodolfo Álvarez-Sala
J. Clin. Med. 2024, 13(15), 4299; https://doi.org/10.3390/jcm13154299 - 23 Jul 2024
Viewed by 506
Abstract
Background: The prevalence of cardiovascular events (CVEs) in patients with asthma varies amongst studies, with little evidence as to their prevalence in patients treated with monoclonal antibodies (mAbs). In this retrospective, observational study, we aimed to evaluate the prevalence of CVEs in [...] Read more.
Background: The prevalence of cardiovascular events (CVEs) in patients with asthma varies amongst studies, with little evidence as to their prevalence in patients treated with monoclonal antibodies (mAbs). In this retrospective, observational study, we aimed to evaluate the prevalence of CVEs in patients with T2 and non-T2 asthma and to identify risk factors associated with CVEs. Methods: A total of 206 patients with severe asthma were included. Demographic variables, respiratory comorbidities and cardiovascular risk factors were collected, along with respiratory function, laboratory parameters and respiratory pharmacotherapy, including treatment with mAbs. Results: A total of 10.7% of the patients had any CVE from the date of asthma diagnosis, with a higher risk in those patients with chronic obstructive pulmonary disease (odds ratio [OR] = 5.36, 95% CI 1.76–16.31; p = 0.003), arterial hypertension (OR = 2.71, 95% CI 1.13–6.55; p = 0.026) and dyslipidaemia (OR = 9.34, 95% CI 3.57–24.44; p < 0.001). No association between mAb treatment and a CVE or between time of mAb treatment and the event was found. No significant differences were observed between the T2 and non-T2 cohort. After a multivariate analysis, dyslipidaemia was identified as an independent risk factor (OR = 13.33, 95% CI 4.49–39.58; p < 0.001), whereas regular use of inhaled corticosteroids was associated with a reduced risk of a CVE (OR = 0.103, 95% CI 0.021–0.499; p = 0.005). Further research is needed to fully understand the relationship between severe asthma and CVEs. Conclusions: This study suggests that patients with severe asthma experience a higher percentage of CVEs compared with the general population. Full article
(This article belongs to the Special Issue Emerging Paradigms in Severe Asthma Management: Integrating Technology and Personalized Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop